Executive Director, Global Marketing, PDAC Cancer Strategy & Ops

Extrait de l’annonce

Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions,…

Le texte complet se lit sur Himalayas. Annonce valable jusqu’au 25 novembre 2026.